[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-dementia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,77,104,128,152,167,196,218,252,275,302],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643954","non-invasive-brain-stimulation-for-memory-loss-in-early-alzheimers-disease-100643954",false,"NCT07667478","NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE","Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible for enrollment:\n\n* A clinical diagnosis of early AD, defined as either mild cognitive impairment (MCI) due to AD or mild dementia due to AD;\n* Evidence of cognitive impairment, characterized by a MMSE score between 20 and 28 and\u002For a CDR-Sum of Boxes score between 0.5 and 8, consistent with the contemporary definitions used in early AD in clinical trials; and\n* Biomarker confirmation of AD pathology, demonstrated by a positive plasma phosphorylated tau-217 (p-tau217) result according to the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic guidelines.\n\nExclusion Criteria:\n\n* Exclusion criteria include evidence of other neurological, psychiatric, or systemic conditions that could cause cognitive and functional impairments (e.g., substantial concomitant cerebrovascular disease, alcoholism, certain medications that could have a substantial effect on cognition, untreated major depressive disorder, and heart, renal or hepatic failure).\n* Individuals who have contraindications to receiving rTMS, including a history of seizures or any non-removable metal in their heads or within 12 inches of the TMS coil will be excluded.","ALL","55 Years","90 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD). The study will also evaluate the safety of this approach.\n\nThe main questions it aims to answer are:\n\n* Does rTMS applied to the cerebellum improve short-term memory in people with early AD?\n* How does this stimulation affect brain activity and connectivity measured by MRI?\n\nResearchers will compare active rTMS to sham rTMS (a look-alike procedure that does not deliver brain stimulation) to see if rTMS works to improve memory.\n\nParticipants will:\n\n* Complete a screening visit with medical and memory assessments\n* Be randomly assigned to receive either active rTMS or sham rTMS (neither participants nor researchers will know the assignment during treatment)\n* Receive 20 rTMS sessions over 4 weeks (about 20 to 30 minutes per session)\n* Undergo two MRI scans, one before and one after treatment\n* Complete memory and thinking tests and questionnaires at baseline, immediately after treatment, and at 3- and 6-month follow-up visits\n\nParticipation in the study will last about 6 months.\n\nThe rTMS is generally well tolerated. The most common side effects include mild headache and scalp discomfort during treatment, which are usually short-lasting. MRI is non-invasive and safe for most people. Study procedures will be reviewed to ensure participant safety.\n\nParticipants may or may not benefit directly from this study. People who receive active rTMS may experience improvement in memory. This research may help improve understanding of memory function in AD and support development of new treatments.",[26,27,28],"Alzheimer s Disease","Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease","Mild Dementia",[30,31,32],"Alzheimer's disease","Mild Cognitive Impairment","Mild dementia","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":37},"2026-04-15",{"date":41,"type":20},"2031-04-14",{"name":43,"class":44},"Chi-Ying (Roy) Lin","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100595024","phase-2-study-to-evaluate-the-efficacy-and-safety-of-kds2010-in-patients-with-alzheimers-disease-with-mild-cognitive-impairment-and-mild-dementia-due-to-alzheimers-disease-100595024","NCT07027072","Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease","Inclusion Criteria:\n\n* Male and female adults aged ≥50 and ≤85 years at the time of written consent\n* Patients with MCI or mild AD confirmed at screening according to the 2024 diagnostic criteria (APPENDIX 1) of the National Institute on Aging-Alzheimer's Association (NIA-AA)\n* Subjects whose total CDR score (CDR-GS) is 0.5 to 1.0 at screening (however, CDR memory score is ≥0.5)\n* Subjects with a Mini-Mental State Examination (MMSE) score of 21 to 30 at screening\n* Subjects who test positive for amyloid on Positron Emission Tomography (PET) during screening\n* Subjects who have a caregiver capable of providing accurate information about the subject's cognitive and functional abilities and appropriate for the planned assessments in the study, as judged by the investigator\n* Subjects (or their legal representatives) who have voluntarily agreed to participate in this study and have given written consent\n\nExclusion Criteria:\n\n* Cognitive impairment or dementia due to causes other than Alzheimer's disease\n\n  * Vascular dementia, central nervous system infections (e.g., HIV, syphilis, etc.), head trauma, Creutzfeldt-Jakob disease, Pick's disease, Huntington's disease, Parkinson's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, thyroid disorders, parathyroid disorders, Vitamin B12 deficiency, folic acid deficiency, other metabolic and nutritional deficiencies, etc.\n  * Alcohol or drug abuse, dependence\n* Subjects with cognitive impairment due to hypothyroidism, nutritional deficiencies, Vitamin B12 or folic acid deficiency as assessed during screening\n* Subjects confirmed during screening to have had the following medical history:\n\n  * Malignant tumors within five years prior to screening except for basal cell carcinoma, cutaneous squamous cell carcinoma, thyroid cancer, or carcinoma in situ that has not recurred in over three years and is considered successfully treated by the investigator\n  * History of alcohol or drug abuse within two years prior to screening\n  * Loss of consciousness of unknown cause, or seizure within the past 52 weeks before screening\n  * Unstable and clinically significant cardiovascular diseases despite appropriate treatment (acute coronary syndrome (ACS), tachycardia, clinically significant arrhythmias, cardiomyopathy, angina of at least CSS III, heart failure of NYHA II-IV, or clinically significant valvular heart disease) within 24 weeks before baseline\n  * Severe or active infectious diseases requiring antibiotics or antivirals within four weeks before baseline\n  * A history of stroke involving a major vascular area, transient ischemic attack (TIA), epilepsy, or severe head trauma with loss of consciousness\n  * Hypersensitivity or allergy to any components of the investigational product\n* Subjects confirmed during screening to have had the following accompanying disease:\n\n  * Clinically significant neurological diseases or serious pathological findings affecting cognitive function as confirmed by brain imaging studies within 52 weeks prior to screening, including multiple sclerosis, normal pressure hydrocephalus, brain tumor (however, exceptions are allowed for lesions diagnosed as benign and with a maximum diameter of less than 1 cm), spinal cord infarction, major hemorrhage (defined as having a diameter \\> 1 cm in MRI) or subdural hemorrhage, cerebral vascular malformation, communicating hydrocephalus, inflammatory demyelinating diseases, etc.\n  * Uncontrolled hypertension despite appropriate treatment at screening or baseline (SBP ≥160 mmHg or DBP ≥100 mmHg)\n  * Dizziness or fainting when standing due to orthostatic hypotension that may affect the evaluation according to the judgment of the investigator\n  * Uncontrolled diabetes (HbA1c \\> 9%) during screening, despite appropriate treatment\n  * Bleeding disorders (Platelet \\\u003C50,000\u002Fmm³) during screening, despite appropriate treatment\n  * Patients with severe hepatic impairment (Child-pugh class C) at screening\n  * Following laboratory test values at screening:\n\n    * AST or ALT \\> 2.5 x ULN\n    * total bilirubin \\> 1.5 x ULN (however, in case of Gilbert syndrome, \\> 3.0 mg\u002FdL)\n    * MDRD eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n  * QTcF interval \\>450 msecs for male or 470 msecs for female(12-lead ECG) during screening\n  * Gastrointestinal diseases that may affect oral administration or absorption (celiac disease, Crohn's disease, intestinal resection, etc.)\n  * Gastrointestinal diseases, including gastric and duodenal ulcers, that may affect the safety evaluation according to the judgment of the investigator\n  * Psychiatric diagnosis or symptoms that may interfere with the study (uncontrolled major depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder, etc.), as assessed by the investigator\n  * Positive responses to items 4 or 5 on the Columbia University Suicide Severity Rating Scale (C-SSRS) during screening\n  * Other conditions deemed by the investigator to potentially affect the outcome of the study\n* Subjects who have undergone or require treatment with the following:\n\n  * AD disease-modifying agents (aducanumab, lecanemab, donanemab, gantenerumab, solanezumab, blarcamesine, simufilam, tricaprilin, valiltramiprosate, etc.) within 12 weeks before screening\n  * Medications that may improve cognitive abilities or affect AD treatment (AChEIs, donepezil, galantamine, rivastigmine, tacrine, memantine, etc.) within 12 weeks before screening, except if the subject has been on a stable dose for at least 12 weeks before baseline and maintains the same composition\u002Fdosage\u002Fmethod of administration during the study period\n  * CNS-active drugs or those affecting cognitive function antidepressants other than serotonergic drugs \\[e.g., bupropion\\], sedatives \\[e.g., carbamazepine\\], dopamine antagonists \\[e.g., antipsychotics, metoclopramide\\], amfepramone, mazindol) within 12 weeks before screening\n  * Central anticholinergics and sedating H1-antihistamines within 12 weeks before screening.\n\nHowever, exceptions are allowed for one-time use of the drugs, such as second-generation H1 antihistamines (e.g., cetirizine, levocetirizine, etc.) or peripheral anticholinergics with no central action (e.g., trospium for treating overactive bladder). But the use is prohibited for at least 3 days from the date of cognitive function evaluation.\n\n* Other investigational products or clinical trial devices within four weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Monoamine oxidase inhibitors (MAOIs) and linezolid within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Opioids (pethidine, tramadol, tapentadol, etc.) within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Cyclobenzaprine and St. John's wort within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* The following serotonergic drugs within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out),\n\n  * selective serotonin (5HT1) agonists\n  * lithium\n  * lamotrigine\n  * ritonavir\n  * dapoxetine\n  * Selective serotonin reuptake inhibitors (SSRIs)\n  * dapoxetine\n  * Serotonin-norepinephrine reuptake inhibitors (SNRIs)\n  * Tricyclic or tetracyclic antidepressants\n  * triazolopyridine antidepressant However, amitriptyline ≤ 50 mg\u002Fday, trazodone ≤ 100 mg\u002Fday, citalopram ≤ 20 mg\u002Fday, and sertraline ≤ 100 mg\u002Fday are allowed without washout.\n* Use of sympathomimetics (ephedrine, methylphenidate, amphetamine, methamphetamine, lisdexamfetamine, etc.) during the screening period\n* Use of Dextromethorphan during the screening period\n* Use of CYP3A4 strong inducer, CYP3A4 strong inhibitor, CYP2D6 strong inducer, and CYP2D6 strong inhibitor during the screening period\n\n  * Inability to undergo MRI or PET scans\n  * Pregnant or breastfeeding women\n  * Fertile women or men who are unwilling to use effective contraception\\* from the date of written consent until 12 weeks after the last administration of the investigational product\n\n    \\*Effective contraception is defined as follows, and at least one method should be used:\n    * Hormonal contraception (oral, injectable, implantable, etc.)\n    * Intrauterine device (IUD) or system (IUS)\n    * Sterilization or surgical procedures (vasectomy, bilateral tubal ligation\u002Fsurgery, hysterectomy)\n    * Dual contraception methods: Simultaneous use of barrier methods (male condoms) with the methods listed above\n    * Absolute abstinence: Total abstinence from sexual intercourse is recognized if the investigator deems the subject's age, occupation, lifestyle, or sexual orientation assures contraception. However, periodic abstinence (calendar method, mucus method, and symptothermal method), withdrawal, and coitus interruptus are not recognized as effective contraception methods.\n  * Other conditions deemed by the investigator to be unsuitable for participation in the study","50 Years","85 Years",{"count":56,"type":20},114,[58],"PHASE2","A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease.\n\nBased on preliminary efficacy observed in the Phase 1 clinical trial, a clinical trial will be conducted in Korea. Eligible patients diagnosed with MCI or mild Alzheimer's disease will be stratified by disease stage (MCI\u002Fmild AD) prior to randomization. Subjects will be randomly assigned in a 1:1:1 ratio to either Treatment Group 1, Treatment Group 2, or the Control Group. The investigational product will be administered orally once daily for a duration of 24 weeks. Approximately 114 subjects will be enrolled, including an estimated 20% dropout rate, with 38 subjects assigned to each group (Treatment Group 1, Treatment Group 2, and Control Group).\n\nThe objectives of the study are as follows:\n\n1. Efficacy Objectives: Efficacy will be evaluated through changes in cognitive function, self-management, and daily living activities before and after administration of KDS2010. Biomarker analysis in plasma and in cerebrospinal fluid (CSF; optional) will also be conducted to explore treatment efficacy.\n2. Safety Objectives: The safety and tolerability will be evaluated after administration of KDS2010.\n3. Exploratory Objectives: The efficacy of Treatment Groups 1 and 2 compared to the Control group will be explored through cognitive endpoints (the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and the Mini-Mental State Examination (MMSE)), stratified by demographic information, tauopathy, and ApoE4 genes.\n\nBased on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at two dose levels: 60 mg and 120 mg.",[61,28,62],"Mild Cognitive Impairment (MCI)","Alzheimer's Disease",[31,28,64,65,62],"KDS2010","MAO-B inhibitor","2026-06-17",{"date":68,"type":37},"2026-06-22",{"date":70,"type":37},"2025-08-06",{"date":72,"type":20},"2027-12-31",{"name":74,"class":75},"NeuroBiogen Co., Ltd","INDUSTRY",8,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100509222","transcranial-pulse-stimulation-of-the-brain-100509222","NCT05910619","Transcranial Pulse Stimulation of the Brain","Transcranial Pulse Stimulation of the Brain in Older Adults With and Without Mild Dementia","Inclusion Criteria:\n\n* Men and women\n* Age: 65 to 84 years\n* English speaking\n* Physically mobile with no history of balance difficulties or major falls\n* For the typically-aging older adult group, phone screening performance on the TICS must be greater than or equal to 33 points, and cognitive performance of 26 points or greater on the MoCA and a Sum of Boxes score of 0 on the Clinical Dementia Rating scale administered to the participant's informant at the initial visit\n* For the Mild dementia group, phone screening performance on the TICS must be between 21 and 32 points, and subsequent cognitive performance of on the MoCA must be \\\u003C23 with a CDR Sum of Boxes score between 4.5 and 9.0 as administered to the participants known informant at the initial visit.\n\nExclusion Criteria:\n\n* Neurological disorders unrelated to dementia \u002F AD (e.g., Parkinson's disease, stroke, seizures, traumatic brain injury)\n* Evidence of greater-than-mild dementia\u002FAD (based on informant CDR Sum of Boxes score greater than 9.0 or MoCA \\\u003C10)\n* Past opportunistic brain infection\n* Major psychiatric illness (schizophrenia, intractable affective disorder, current substance dependence diagnosis or severe major depression and\u002For suicidality) or any history of agitation and\u002For delirium\n* Unstable (e.g., cancer other than basal cell skin) and chronic (e.g., diabetes mellitus) medical conditions\n* MRI contraindications (e.g., pregnancy, claustrophobia, metal implants that are contraindicated for MRI and TPS)\n* Physical impairment precluding motor response or lying still for one hour and inability to walk two blocks without stopping or without balance difficulties\n* Drug exclusions include those medications that are known to have cognitively sedating or altering effects as well medications with a strong anticholinergic burden or CNS effects. Participants should be stable on any recently altered medications\u002Fdosages for at least four weeks prior to beginning the study. Medications will be reviewed during the interview for the purpose of identification of contraindicated pharmacological agents with common cognitive side-effects\n* Other history of medical conditions that may increase risk of cerebrovascular events, including prior heart attack, cardiac arrhythmia such as atrial fibrillation\n* Hearing or vision deficits that will not allow for reliable standardized cognitive assessment; i.e. colorblindness, inability to hear through headphones (with or without hearing aids), macular degeneration or other significant diseases that cause severe loss of vision. If vision is corrected with lenses to appropriate levels, then participant will be eligible\n* Left-handedness and ambidextrousness, as these individuals have a higher percentage rate of atypical functional lateralization for brain functions, which would significantly interfere with interpretability of brain data\n* Hemophilia or other blood clotting disorders or thrombosis\n* Corticosteroid treatment within the last six weeks before the first treatment","65 Years","84 Years",{"count":87,"type":20},20,[23],"This study will investigate transcranial pulse stimulation (TPS) as a method of enhancing cognitive and neural function. The study team will apply this low intensity, magnetically pulse technology to key brain regions in a randomized, sham-controlled trial (RCT). The study will determine the magnitude of changes in cognitive function and brain function and structure between a pre- and post-stimulation among 10 typically-aging older adults and 10 patients with mild dementia.",[28,91],"Aging Well",[28,93,94],"Typical Aging","Transcranial Pulse Stimulation","2026-04-28",{"date":97,"type":37},"2026-04-29",{"date":99,"type":37},"2024-02-16",{"date":101,"type":20},"2026-12-07",{"name":103,"class":44},"University of Florida",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":45},"100525423","the-swedish-biofinder---preclinical-ad-study-100525423","NCT06121544","The Swedish BioFINDER - Preclinical AD Study","Inclusion Criteria:\n\n1. Age 50-80\n2. Individuals aged 50-60 require at least one of the following risk factors for AD:\n\n   1. Known apolipoprotein E (APOE) -ε4 carrier\n   2. Known 1st degree family history of dementia or severe memory loss with onset prior to 75.\n   3. Known amyloid brain pathology by either CSF or PET scan.\n3. Mini-Mental State Examination (MMSE) ≥26 (aged \\>65); MMSE ≥27 (aged 50-65).\n4. Score of 12 or above on the Montreal Cognitive Assessment (MoCA) telephone version.\n5. Speaks and understands Swedish to the extent that an interpreter is not necessary to fully understand the study information and cognitive tests.\n\n6a. Preclinical Alzheimer's disease subgroup (n=450): Amyloid pathology according to cerebrospinal fluid Alzheimer's disease and amyloid PET scans.\n\n6b. Non-Preclinical Alzheimer's disease subgroup (n=150): No sign of preclinical Alzheimer's disease using cerebrospinal fluid Alzheimer's disease biomarkers or Aβ-PET scans.\n\nExclusion Criteria:\n\n1. Fulfils the criteria for minor or major neurocognitive disorder according to The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n2. History of significant brain injury or other known neurologic disease or insult, resulting in lasting cognitive sequelae that would confound the assessment and staging of potential neurodegenerative disease.\n3. Major depression, bipolar disorder, or recurrent psychotic disorders within the past year.\n4. History of alcohol and\u002For substance abuse or dependence within the past year.\n5. Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n6. Refusing or unable to complete baseline cognitive and biomarker assessments (i.e., cognitive testing, blood draw, MRI and PET).","80 Years",{"count":112,"type":20},800,"OBSERVATIONAL","This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Skåne University Hospital in Sweden. The study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3\u002F4 having preclinical Alzheimer's disease. Recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure.",[116,31,28],"Alzheimer Disease",[118],"Preclinical Alzheimer, early diagnosis, biomarkers, plasma, CSF, PET","2026-04-01",{"date":121,"type":37},"2026-04-06",{"date":123,"type":37},"2022-04-01",{"date":125,"type":20},"2026-12-31",{"name":127,"class":44},"Skane University Hospital",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":15,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":138,"conditions":139,"keywords":144,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":45},"100525332","the-swedish-biofinder---primary-care-study-100525332","NCT06120361","The Swedish BioFINDER - Primary Care Study","ADetect","Inclusion Criteria:\n\n1. The patient seeks medical help because of cognitive symptoms experienced by the patient and\u002For informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment.\n2. The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints.\n3. Age ≥40 years\n4. Subjective cognitive decline, mild cognitive impairment or mild dementia\n\nExclusion Criteria:\n\n1. Already diagnosed dementia\n2. Significant unstable systemic illness or organ failure that makes it difficult to participate.\n3. Current significant alcohol or substance misuse.\n4. Refusing investigation at the Memory clinic\n5. Cognitive impairment with acute onset due to stroke\n6. The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.","40 Years",{"count":137,"type":20},1200,"The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics. The investigators will strive to recruit diverse and representative populations of patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and mild dementia. The specific aims of the study are to:\n\n1. Improve the detection of mild cognitive impairment (MCI) and dementia in primary care.\n2. Develop and evaluate cognitive tests, blood-based biomarkers and brain imaging methods that are suitable for accurate and early diagnosis of Alzheimer's disease (AD) in primary care.\n3. To prospectively validate plasma AD biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in primary care.\n4. Determine whether blood AD biomarkers improve patient management in primary care.",[28,31,140,116,141,142,143],"SCD","Lewy Body Disease","Frontotemporal Degeneration","Vascular Dementia",[145],"Primary care, early diagnosis, blood, biomarkers, cognitive testing",{"date":121,"type":37},{"date":148,"type":37},"2020-01-01",{"date":150,"type":20},"2028-12-31",{"name":127,"class":44},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":166,"locationsCount":45},"100525490","the-swedish-biofinder---memory-clinic-study-100525490","NCT06122415","The Swedish BioFINDER - Memory Clinic Study","Validate","Inclusion Criteria:\n\n1. Under investigation for cognitive symptoms at the Memory clinic.\n2. Cerebrospinal fluid and blood sampling is planned to be done as part of clinical practice even if the patient is not taking part of this study.\n\nExclusion Criteria:\n\n1. Not undergoing CSF or blood sampling as part of clinical practice.\n2. Not undergoing cognitive testing as part of clinical practice.",{"count":137,"type":20},"The diagnosis of diseases causing memory difficulties or dementia is often challenging. Without the use of advanced methods such as cerebrospinal fluid tests, approximately 25-30% do not receive a correct diagnosis today. However, the investigators have recently developed new blood biomarkers with high diagnostic accuracy, and the investigators now want to investigate whether they can eventually replace cerebrospinal fluid tests. This is because blood tests are much more cost-effective and significantly easier for patients compared to cerebrospinal fluid tests.\n\nIn this study, 1200 patients undergoing clinical evaluations at the Memory Clinic, Skåne University Hospital in Malmö, are included for blood and cerebrospinal fluid sample collection. The blood samples are sent for analysis using the new blood biomarkers. Subsequently, the results are compared with those from the clinical analysis of cerebrospinal fluid to determine how well they perform in routine clinical practice as an alternative to cerebrospinal fluid tests and whether the blood test improves patient care. This comparison is carried out by the attending physician in three steps:\n\n1. Assessment without access to the results of either the blood test or cerebrospinal fluid test.\n2. Assessment with access to only the results of the blood test.\n3. Assessment with access to the results of both the blood test and cerebrospinal fluid test.\n\nAim 1) To prospectively validate plasma Alzheimer's disease (AD) biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in a specialist memory clinic.\n\nAim 2) Determine whether blood AD biomarkers improve patient management in specialist memory clinic settings.",[28,31,140,116,141,142,143],{"date":121,"type":37},{"date":164,"type":37},"2022-12-01",{"date":125,"type":20},{"name":127,"class":44},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":175,"sex":15,"minAge":176,"maxAge":17,"enrollmentInfo":177,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":45},"100631767","dementia-friendly-apothecaries-as-a-resource-for-mental-heath-in-the-elderly-100631767","NCT07504965","Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly","Demenz-freundliche Apotheken Als Ressource für Psychische Gesundheit im Alter","DARE","Inclusion Criteria\n\n1. Age: Participants must be 60 years or older at the time of consent.\n2. Language Proficiency: Sufficient knowledge of the German language to understand instructions and participate in the study.\n3. Cognitive Status: Presence of self-reported, relative-reported, or pharmacist-identified cognitive impairments (e.g., memory problems or mild cognitive changes).\n4. Consent: Ability to provide informed consent voluntarily.\n\nExclusion Criteria\n\n1. Severe Sensory Impairments: Participants unable to see or hear well enough to complete the digital assessments or questionnaires.\n2. Previous Dementia Diagnosis: Individuals with a prior formal diagnosis of dementia, whether with or without underlying pathology.\n3. Severe Cognitive or Physical Impairments: Any condition that would prevent meaningful participation in the digital tests or structured screening process.\n\nThese criteria aim to ensure that the study includes participants at risk of early cognitive decline while excluding those for whom the interventions or assessments would not be feasible or relevant.",true,"60 Years",{"count":178,"type":20},1020,"The DARE study (Dementia-Friendly Apothecaries as a Resource for Mental Health in the Elderly) is a multicenter, prospective cohort study aiming to identify individuals with cognitive impairments early in pharmacies and enhance their access to support services. Partner pharmacies are equipped with memory test stations, and pharmaceutical staff are trained to guide participants. The digital memory test evaluates cognitive, psychosocial, and health factors, displaying results in a traffic light graphic. Participants with concerning results are referred to specialists or support services.\n\nThe study's primary goals are to establish pharmacies as dementia screening hubs, improve care for affected individuals, promote interdisciplinary collaboration, and lay the groundwork for legal and billing frameworks. An optional subproject validates the screening through neurological evaluations.",[31,28],[182,183,184,185,186,187],"Dementia-friendly pharmacies","Cognitive impairment","Early detection","Accessible healthcare","Digital cognitive assessments","Prevention of dementia","2026-03-26",{"date":119,"type":37},{"date":191,"type":37},"2025-07-01",{"date":193,"type":20},"2027-07-31",{"name":195,"class":44},"Ludwig-Maximilians - University of Munich",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":175,"sex":15,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":45},"100617666","activity-tracking-care-partner-co-participation-text-reminders-instructional-education-video-guided-physical-rehabilitation-and-exercise-100617666","NCT07321587","Activity Tracking, Care Partner Co-participation, Text Reminders, Instructional Education, Video-Guided Physical Rehabilitation, and Exercise","Activity Tracking, Care Partner Co-participation, Text Reminders, Instructional Education, Video-Guided Physical Rehabilitation, and Exercise (ACTIVE) Intervention Among Older Adults With and Without Mild Dementia","ACTIVE","Inclusion Criteria:\n\nOlder Adults:\n\n* Age ≥65 years.\n* With or without mild dementia.\n* Willing to consent to participate in the study or have an LAR that is willing to consent for their participation in the study\n* Willing to wear a Fitbit smartwatch, receive text messages, watch intervention-related videos, participate in physical therapy, and walking exercise.\n* No contraindications to engaging in physical activity.\n\nCare Partners:\n\n* Age ≥18 years.\n* Met criteria for survey participation.\n* Person being cared for is recruited in the study.\n* Willing to consent to participation\n* Willing to wear a Fitbit smartwatch, receive text messages, watch intervention-related videos, participate in physical therapy, and walking exercise.\n* No contraindications to engaging in physical activity.\n\nExclusion Criteria:\n\nOlder Adults:\n\n* Severe cardiac, neurologic, or musculoskeletal condition (including but not limited to recent or untreated fracture in any part of the body)\n* limiting participation in daily walking or Fitbit smartwatch use.\n* Moderate to severe dementia (using the clinical dementia rating scale of 2 or higher\n* Inability to operate or manage a Fitbit smartwatch device (even with care partner support).\n* No phone or phone not capable of receiving text messages or watching videos.\n* No internet for watching videos\n\nCare Partners:\n\n* Severe cardiac, neurologic, or musculoskeletal condition limiting participation in daily walking or Fitbit smartwatch use.\n* Pregnant care partners\n* Any level of dementia or cognitive impairment among care partners\n* Inability to operate or manage a Fitbit smartwatch device.\n* Inability to co-participate in intervention tasks with older adult\n* No phone or phone not capable of receiving text messages or watching videos.\n* No internet for watching videos","18 Years",{"count":206,"type":20},100,[23],"This is a multi-methods two-arm, crossover, analyst-blinded randomized controlled trial with embedded qualitative interviews, enrolling 50 dyads (older adult-care partner). Participants will receive the ACTIVE intervention, which includes a Fitbit smartwatch, motivational text messages to engage in walking exercise, instructional educational videos, and virtual physical therapy sessions. Intervention components will be delivered over 3 weeks, with continuous monitoring of physical activity via Fitbit data, read receipts of the motivational text messages, and log of engagement in the virtual physical therapy and educational videos.",[28],"2026-01-26",{"date":212,"type":37},"2026-01-28",{"date":210,"type":37},{"date":215,"type":20},"2027-12",{"name":217,"class":44},"NYU Langone Health",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100610959","sensory-enrichment-using-aromatherapy-for-neurobehavioral-and-psychological-symptoms-in-early-dementia-100610959","NCT07234357","Sensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia","Sensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia (SENSE)","SENSE","Inclusion Criteria:\n\nFor patients:\n\n* Aged 50 years old and above.\n* Confirmed diagnosis of MCI or mild dementia based on clinical records.\n* Has one identified caregiver aged 21 years and above who is willing to provide written informed consent for his\u002Fher own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥2 hours\u002Fday ≥3 days\u002Fweek; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study intervention.\n\nFor caregivers:\n\n* Aged 21 years old and above.\n* Willing and able to provide written informed consent\n* Identified as the caregiver for recruited patient in this study can read, understand, and speak the designated language at the study site; either lives with the recruited patients or sees the patient for ≥2 hours\u002Fday ≥3 days\u002Fweek.\n* Agrees to accompany the patient to each study visit; and can verify daily compliance with study intervention.\n\nExclusion Criteria:\n\nFor patients:\n\n* Olfactory impaired\u002Fdysfunctional.\n* Known or suspected hypersensitivity\u002Fallergy to essential oils or any components of the formulations.\n* Has Reactive Airway Disease (e.g, Asthma).\n* Participant without a caregiver.\n* Pregnant, breastfeeding, or intending to conceive during study period.\n\nFor caregivers:\n\n* Physically or mentally incapable of providing verbal \u002F written consent\n* Does not have regular or meaningful contact with the participant (e.g. less than 2 hours\u002Fday or less than 3 days\u002Fweek).\n* Not able to follow patient to each study visit.","99 Years",{"count":228,"type":20},200,[23],"To determine if diffusion aromatherapy exposure to an essential oil blend can potentially improve mild cognitive impairment\u002Fmild dementia symptoms and relieve caregiver stress.\n\nThis study also allows us to gauge the willingness of elderly patients in complying with long-term aromatherapy treatments.",[31,28],[233,234,235,61,28,236,237,238,239,240],"Aromatherapy","Diffusion Aromatherapy","Essential Oils","Dementia","Caregiver Burden","Caregiver Stress","Elderly Compliance","Caregiver","NOT_YET_RECRUITING","2025-11-14",{"date":244,"type":37},"2025-11-18",{"date":246,"type":20},"2025-11",{"date":248,"type":20},"2026-11",{"name":250,"class":44},"National Cancer Centre, Singapore",2,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":15,"minAge":204,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":45},"100608946","share-adaptation-intervention-for-african-american-families-100608946","NCT07208162","SHARE Adaptation Intervention for African-American Families","Adapting the SHARE for Dementia Early-Stage Dyadic Intervention: A Stage I Pilot Study With African-American Families","SHARE","Inclusion Criteria:\n\n* African American dyads (both the caregivers and the care-recipient, an individual with an early-stage memory impairing condition (e.g., Alzheimer's disease, vascular dementia, cognitive impairment, etc.)\n* Care-recipient lives at home.\n* The caregiver (CG) and\u002For the person with dementia (PWD), or symptoms of memory loss must identify as African American.\n* PWD must be at least 50 years old and CGs 18 or older,\n* Ability to speak and read English,\n* Experiencing signs and symptoms of mild to moderate dementia through family caregiver report on the Dementia Severity Rating Scale and meeting the National Institute on Aging and the Alzheimer's Association clinical criteria for probable AD.\n\nExclusion Criteria:\n\n* A mental health condition (e.g., schizophrenia, bipolar disorder, major depression)\n* A traumatic brain injury\n* Intellectual or developmental disability\n* Individuals experiencing extreme difficulty adjusting and coping to the diagnosis • Individuals living in an institutional setting",{"count":261,"type":20},120,[23],"This project aims to culturally adapt the SHARE program for African-Americans in early-moderate stage dementia and their care partner. Upon completion of the adaptation, a pilot randomized-control trial wil be confucted to compare the adaptaed SHARE program versus usual care.",[28,265],"Moderate Dementia","2025-09-28",{"date":268,"type":37},"2025-10-06",{"date":270,"type":37},"2025-08-19",{"date":272,"type":20},"2026-07",{"name":274,"class":44},"Benjamin Rose Institute on Aging",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":15,"minAge":176,"maxAge":17,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":45},"100507460","shanghai-non-pharmacological-intervention-for-mild-cognitive-impairment-and-mild-alzheimers-disease-100507460","NCT05887674","Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease","Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease: Combined Low Inflammatory-index Diet, Physical Exercises, and Cognitive Training in Nursing Home","SIM-2","Inclusion Criteria:\n\n1. Aged 60-90 years\n2. In accordance with the diagnostic criteria for \"mild cognitive impairment due to Alzheimer's disease\" or \"mild Alzheimer's disease\" from the National Institutes of Health National Institute on Aging-Alzheimer's Association (NIA-AA) (2011)\n3. The Hamilton depression rating scale\u002F17 edition (HAMD) total score≤10\n4. Neurological examination: no obvious signs\n5. Education: primary school (grade 6) or above and capacity to complete tests for cognitive ability\n6. Capacity to give consent\n\nExclusion Criteria:\n\n1. Other causes of cognitive decline: cerebrovascular disease, central nervous system infection, Creutzfeldt-Jakob disease, Huntington's and Parkinson's disease, Creutzfeldt-Jakob disease, traumatic brain dementia, other physical and chemical factors (such as drugs, alcohol, CO), systemic disease (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial occupation (a subdural hematoma, brain tumor), the endocrine system disease (thyroid disease, parathyroid disease), and vitamins deficiency or any other causes of dementia\n2. The history of nervous system diseases, including stroke, optic myelitis, Parkinson's disease, epilepsy, etc\n3. Psychiatric patients, including schizophrenia or other mental illnesses, bipolar disorder, major depression, or delirium\n4. There are unstable or serious heart, lung, liver, kidney, endocrine, and hematopoietic system diseases, or Poor prognosis because of malignant diseases such as tumors.\n5. Vision or hearing problems that lead to poor performance on cognitive tests\n6. Two years history of severe alcoholism, and drug abuse\n7. Participants who participated in any other trial 30 days prior to their screening visit\n8. Contraindication of MRI scanning\n9. Special requirements for diet, e.g., allergy to common food or on a special diet due to medical needs\n10. Participants who cannot be followed for at least 6 months (due to a health situation or migration)",{"count":284,"type":20},180,[23],"This study is a multicentre, randomized, double-blind, controlled trial that aims to investigate the efficacy of multi-domain life-style intervention including low inflammatory-index diet, exercise, and cognitive training in patients with mild cognitive impairment and mild Alzheimer's disease.",[31,28],[289,30,290,291,292],"mild cognitive impairment","Diet","Physical exercise","Cognitive training","2024-11-21",{"date":295,"type":37},"2024-11-22",{"date":297,"type":37},"2023-05-11",{"date":299,"type":20},"2026-08-30",{"name":301,"class":44},"Ruijin Hospital",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":175,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":21,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":45},"100530302","resistance-training-to-individuals-for-cognitive-impairment-with-dementia-100530302","NCT06185010","Resistance Training to Individuals for Cognitive Impairment With Dementia","Effects of Different Resistance Training Volumes on Cognitive Function, Oxidative Stress, Immunological Response, Lipid Profile, Glycemic Status, Liver Function, Muscle Function, Hemodynamic Response, and Physical Performance in Individuals With Mild Cognitive Impairment","TRAIN4BRAIN","Inclusion criteria:\n\n* Clinical diagnosis of mild cognitive impairment\n* SPPB score ≥ 3 points\n* Willingness to participate in the interventions and collaborate with the research team\n* Must be able to provide informed consent (oral or written)\n\nExclusion criteria:\n\n* Severe dementia\n* Severe comorbidity that negatively influences participation in the intervention\n* Color blindness\n* Fractures in the last three months",{"count":311,"type":20},80,[23],"This research project aims to analyze the effects of different resistance training volumes on cognitive function, oxidative stress, immunological response, lipid profile, glycemic status, liver function, muscle function, hemodynamic response, and physical performance in individuals with mild cognitive impairment. First the investigators will analyze the effects of a single resistance training session (acute effects) with one and three sets on hemodynamic and physical performance in individuals with mild cognitive impairment. After, the investigators will analyze the effects of an 8-week resistance training program with one or three sets on cognitive function, oxidative stress, immunological response, lipid profile, glycemic status, liver function, muscle function, hemodynamic response, and physical performance in individuals with mild cognitive impairment. The investigators hypothesize that a single resistance training session of one or three sets will increase the acute hemodynamic and physical performance stress in individuals with mild cognitive impairment, although with a higher magnitude in the session with three sets. Furthermore, we hypothesize that eight weeks of resistance training with one or three sets will induce similar improvements in cognitive function, oxidative stress, immunological response, lipid profile, glycemic status, liver function, muscle function, hemodynamic response, and physical performance in individuals with mild cognitive impairment.",[31,28],"2024-08-01",{"date":317,"type":37},"2024-08-06",{"date":319,"type":37},"2023-12-01",{"date":321,"type":20},"2024-12-31",{"name":323,"class":44},"University of Beira Interior"]